Level of chromosomal abnormality in NSCLC may predict response to immunotherapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Patients with non-small cell lung cancer (whose cancer cells have low levels of—an abnormal number of chromosomes—tend to respond better to immune checkpoint inhibitor drugs than patients with higher levels, Dana-Farber Cancer Institute researchers found. 

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In the days leading up to the 2021 American Society of Clinical Oncology annual meeting, The Cancer Letter published a piece focused on Axel Grothey’s unethical sexual relationships with women he mentored while at Mayo Clinic. While this news was met by some as shocking, science tells us it is anything but.

Login